Weight problems: Diabetes drug hailed as a ‘sport changer’ after trial reveals dramatic weight reduction

File photo dated 24/09/18 of an obese woman. Lesbian and bisexual women are at greater risk of being overweight than heterosexual women, research suggests.

A drug that suppresses urge for food has been described as a “gamechanger” within the combat in opposition to weight problems after analysis confirmed it may reduce physique weight by as much as 20%.

The research into the results of semaglutide on weight problems by a College Faculty London (UCL) workforce discovered that multiple third (35%) of people that took it misplaced greater than one-fifth of their whole physique weight.

Researchers say it implies that for the primary time it’s attainable to attain by way of medication what was beforehand solely attainable by way of weight reduction surgical procedure.

The destructive well being implications of weight problems have been introduced into even sharper focus by the COVID-19 disaster due to its effect on mortality rates.

Semaglutide works by hijacking the physique’s personal urge for food regulating system within the mind, resulting in decreased starvation and calorie consumption.

The UCL randomised management trial concerned 1,961 adults who had been both obese or overweight (common weight 105kg/16.5 stone, physique mass index 38kg/m2), and occurred at 129 websites in 16 international locations throughout Asia, Europe, North America, and South America.

Contributors took a 2.4mg dose of semaglutide or matching placebo weekly by way of an injection below the pores and skin.

Total, 94.3% of contributors accomplished the 68-week research, which began in autumn 2018.

These participating additionally obtained particular person face-to-face or telephone counselling periods from registered dietitians each 4 weeks to assist them adhere to the reduced-calorie food regimen and elevated bodily exercise, offering steerage, behavioural methods and motivation.

In these taking semaglutide, the common weight reduction was 15.3kg (2.four stone), with a discount in BMI of 5.54.

The placebo group noticed a median weight lack of 2.6kg (0.four stone) with a discount in BMI of 0.92.

Publishing the information within the New England Journal for Drugs, lead writer, Professor Rachel Batterham from UCL’s Centre for Weight problems Analysis, mentioned: “The findings of this research symbolize a serious breakthrough for bettering the well being of individuals with weight problems.

“Three quarters (75%) of people that obtained semaglutide 2.4mg misplaced greater than 10% of their physique weight and greater than one-third misplaced greater than 20%.

“No different drug has come near producing this stage of weight reduction – this actually is a sport changer.

“For the primary time, individuals can obtain by way of medication what was solely attainable by way of weight reduction surgical procedure.”

Professor Batterham added that the drug may have main implications for UK well being coverage for years to return.

Together with the burden loss, the group taking semaglutide noticed reductions in danger components for coronary heart illness and diabetes, similar to waist circumference, blood fat, blood sugar and blood stress, and reported enhancements of their general high quality of life.

Semaglutide is already clinically accredited to be used by sufferers with kind 2 diabetes, although at decrease doses than used within the weight problems trial.

Proof from the research has been submitted for regulatory approval as a remedy for weight problems to the Nationwide Institute of Scientific Excellence (NICE), the European Medicines Company (EMA) and the US Meals and Drug Administration (FDA).

Source link